BioPharma Resources

NDA 221276 · Glaxosmithkline

Hibsago

Bepirovirsen Sodium · Subcutaneous

NovelPriority review

CDER novel approval, Oct 20, 2026: To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Oct 20, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

13

2 Phase 3, 0 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ON-TREATMENT HEPATIC FLARES AND THROMBOCYTOPENIA On-Treatment Hepatic Flares HIBSAGO may cause on-treatment hepatic flares with increases in ALT of >20-40x ULN associated with decline in HBsAg. Some cases were associated with hyperbilirubinemia. Most occurred in the first 12 weeks of treatment and resolved when treatment was interrupted or permanently discontinued [see Warnings and Precautions ( 5.1 ), Adverse Reactions ( 6.1 )] . ALT and total bilirubin must be measured prior to initiation of HIBSAGO and frequently monitored during treatment [see Dosage and Administration ( 2.4 ), Warnings and Precautions ( 5.1 )] . Do not initiate HIBSAGO in patients with evidence of acute hepatic impairment or cirrhosis [see Contraindications ( 4 )] . Interruption of treatment, followed by reducing the dose or discontinuation of HIBSAGO, may be necessary based on the results of liver...

What it is approved for

From the label in effect Oct 20, 2026.

HIBSAGO is indicated in combination with nucleos(t)ide analog reverse transcriptase inhibitor (NrtI) therapy for treatment of chronic hepatitis B virus (HBV) infection in adult patients without cirrhosis: • who have been on NrtI therapy for at least 6 months and have suppressed HBV deoxyribonucleic acid (DNA), and • who have HBV surface antigen (HBsAg) levels less than or equal to 3,000 IU/mL as determined by an FDA-authorized test [see Dosage and Administration ( 2.2 )] . HIBSAGO is a hepatitis B virus (HBV) mRNA-directed antisense oligonucleotide (ASO) indicated in combination with nucleos(t)ide analog reverse transcriptase inhibitor (NrtI) therapy for treatment of chronic HBV infection in adult patients without cirrhosis: • who have been on NrtI therapy for at least 6 months and have suppressed HBV deoxyribonucleic acid (DNA), and • who have HBV surface antigen (HBsAg) levels less than or equal to 3,000 IU/mL as determined by an FDA-authorized test. ( 2.2 )

Mechanism: HIBSAGO is an antiviral drug against HBV [see Microbiology ( 12.4 )] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • HIBSAGO · BEPIROVIRSEN SODIUM EQ 150MG BASE/ML (EQ 150MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bepirovirsen" as an intervention, any sponsor and status, largest first.

All 13 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 13 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.